Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
13 December 2021 - 10:00PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company focused on developing treatments for obesity and liver
diseases, today announced the appointment of Richard Eisenstadt as
Chief Financial Officer, effective December 31, 2021. Mr.
Eisenstadt succeeds Will Brown, who is leaving Altimmune to pursue
other opportunities.
“We are excited to welcome Rich to Altimmune and
our executive management team. His extensive experience in
financing and managing drug development and commercial operations
will help ensure the company’s continued success,” said Vipin K.
Garg Ph.D., President and Chief Executive Officer. “I’ve had the
pleasure of working with Rich previously and this is an opportune
time for him to join our team as we accelerate the clinical
development of pemvidutide, a potential best-in-class treatment for
obesity and NASH, and HepTcell, an exciting immunotherapeutic and a
potential functional cure for chronic hepatitis B. I would like to
thank Will for his contributions over the past years and wish him
well in his future endeavors.”
Mr. Eisenstadt added, “I am delighted to join
Altimmune and look forward to building on the accomplishments of
the team. With the upcoming data readouts in 2022, there is
substantial opportunity to grow and advance the company’s clinical
pipeline and I am excited for the journey ahead.”
Mr. Eisenstadt is an accomplished executive with
over 30 years of leadership experience in healthcare, life
sciences, and emerging technology industries. He joins Altimmune
from Aytu BioPharma, Inc., where he served as Chief Financial
Officer following its merger with Neos Therapeutics, Inc. in March
2021. While Chief Financial Officer at Neos, he raised over $340
million in private and public equity and debt financings and
supported the transition of the company from clinical stage to
commercial operations. Prior to Neos, Mr. Eisenstadt served as
Chief Financial Officer at Arborgen, Inc., and prior to that, Chief
Financial Officer at Tranzyme, Inc., where he was instrumental in
its initial public offering, negotiating several licensing
agreements, and financing the company through late-stage clinical
development. Mr. Eisenstadt received an M.B.A. from James Madison
University and a B.A. in Economics from the University of North
Carolina at Chapel Hill.
About AltimmuneAltimmune is a
clinical stage biopharmaceutical company focused on developing
treatments for obesity and liver diseases. Altimmune’s pipeline
includes next generation peptide therapeutics for obesity, NASH
(pemvidutide), and chronic hepatitis B (HepTcell™). For more
information on Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor & Media
Contacts:
Vipin K. Garg,
Ph.D. President
and Chief Executive Officer
Phone:
240-654-1450 vgarg@altimmune.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024